Hemoadsorption does not Have Influence on Hemolysis During Cardiopulmonary Bypass

Area of Science:

• Cardiovascular Surgery
• Hemostasis and Thrombosis
• Biomaterials and Medical Devices

Background:

• Cardiopulmonary bypass (CPB) is associated with hemolysis, leading to elevated plasma free hemoglobin.
• Hemolysis during CPB can contribute to postoperative complications.
• Novel hemoadsorption devices aim to mitigate adverse effects during CPB.

Purpose of the Study:

• To investigate the effect of a novel hemoadsorption device on hemolysis during CPB.
• To analyze changes in plasma free hemoglobin, haptoglobin, lactate dehydrogenase, and bilirubin levels.
• To evaluate the efficacy of hemoadsorption in reducing CPB-induced hemolysis.

Main Methods:

• Post hoc analysis of a single-center, blinded, controlled study.
• Inclusion of 35 patients undergoing elective CPB surgery with expected CPB duration > 120 minutes.
• Comparison between a hemoadsorption intervention group (n=17) and a control group (n=18).

Main Results:

• No significant difference in postoperative free hemoglobin levels between groups.
• Statistically significant differences in median haptoglobin levels (58.4 vs. 17.9 mg/dL; P < 0.01) on postoperative day 1.
• Significant differences in median lactate dehydrogenase levels (353.0 vs. 432.0 U/L; P < 0.05) on postoperative day 1.

Conclusions:

• The hemoadsorption device did not demonstrate a significant effect on reducing hemolysis markers during CPB in this study.
• Lower haptoglobin and higher secondary hemolysis markers in the control group suggest a potential moderate effect of the device.
• Larger studies are required to confirm the clinical significance of the observed differences.